308 related articles for article (PubMed ID: 19826113)
1. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
[TBL] [Abstract][Full Text] [Related]
2. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H; Lheureux S; Fleming GF; Sugimoto A; Morgan R; Biagi J; Wang L; McGill S; Ivy SP; Oza AM
Gynecol Oncol; 2015 Jul; 138(1):55-61. PubMed ID: 25895616
[TBL] [Abstract][Full Text] [Related]
5. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Raja FA; Griffin CL; Qian W; Hirte H; Parmar MK; Swart AM; Ledermann JA
Br J Cancer; 2011 Sep; 105(7):884-9. PubMed ID: 21878941
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
[TBL] [Abstract][Full Text] [Related]
8. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
10. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
[TBL] [Abstract][Full Text] [Related]
11. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
Piura B; Rabinovich A
Eur J Gynaecol Oncol; 2004; 25(4):449-52. PubMed ID: 15285301
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Penson RT; Moore KM; Fleming GF; Braly P; Schimp V; Nguyen H; Matulonis UA; Banerjee S; Haluska P; Gore M; Bodurka DC; Hozak RR; Joshi A; Xu Y; Schwartz JD; McGuire WP
Gynecol Oncol; 2014 Sep; 134(3):478-85. PubMed ID: 25016924
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Kavanagh JJ; Sill MW; Ramirez PT; Warshal D; Pearl ML; Morgan MA
Int J Gynecol Cancer; 2008; 18(3):460-4. PubMed ID: 17854432
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Friberg G; Kasza K; Faoro L; Salgia R; Stadler WM; Vokes EE; Fleming GF; ; ;
Gynecol Oncol; 2008 Jul; 110(1):49-55. PubMed ID: 18423560
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gold MA; Brady WE; Lankes HA; Rose PG; Kelley JL; De Geest K; Crispens MA; Resnick KE; Howell SB
Gynecol Oncol; 2012 Jun; 125(3):635-9. PubMed ID: 22446624
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Cowan M; Swetzig WM; Adorno-Cruz V; Pineda MJ; Neubauer NL; Berry E; Lurain JR; Shahabi S; Taiym D; Nelson V; O'Shea KL; Kocherginsky M; Matei D
Gynecol Oncol; 2021 Oct; 163(1):57-63. PubMed ID: 34419285
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Gupta R; Cristea M; Frankel P; Ruel C; Chen C; Wang Y; Morgan R; Leong L; Chow W; Koczywas M; Koehler S; Lim D; Luu T; Martel C; McNamara M; Somlo G; Twardowski P; Yen Y; Idorenyi A; Raechelle T; Carroll M; Chung V
Cancer Treat Res Commun; 2019; 21():100155. PubMed ID: 31279962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
